This article is more than 5 years old. Information may no longer be current.
Phase 2 trial begins for patients with acute adenovirus conjunctivitis
Click Here to Manage Email Alerts
Okogen initiated its phase 2 clinical trial, RUBY, for OKG-0301, a topical ophthalmic formulation of ranpirnase, in patients with acute adenoviral conjunctivitis.
Ranpirnase is a targeted ribonuclease (RNase) with established broad-spectrum antiviral properties, the company said in a press release.
Naturally present in tears, RNases have evolved as host defense tools, and OKG-0301 functions through multiple mechanisms to halt viral replication and reduce inflammation, according to Okogen.
The RUBY trial is a phase 2, multicenter, randomized, placebo-controlled, double-masked clinical trial evaluating multiple doses of OKG-0301 in 219 adult patients with acute adenoviral conjunctivitis. Stephanie Watson, Bsc(Med), MBBS, FRANZCO, PhD, professor at the University of Sydney is coordinating principle investigator.
The study will evaluate the ability of OKG-0301 to reduce viral burden and investigators will assess the treatment’s safety and potential to diminish longer-term complications of adenoviral infection that negatively affect vision and lead to scarring of the ocular surface, according to the release.